Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Minor Stroke or TIA - Trial NCT06358313
Access comprehensive clinical trial information for NCT06358313 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kafrelsheikh University
Timeline & Enrollment
Phase 3
Apr 10, 2024
May 10, 2025
Primary Outcome
the rate of new stroke at 90 days
Summary
Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in
 the first 24 hours on the clinical outcomes of first-ever minor stroke or TIA patients
 treated with clopidogrel and aspirin assessed through NIHSS, mRS, and possible adverse
 effects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06358313
Non-Device Trial